Risperdal Trial Settles On Day Of Trial

Johnson & Johnson reached a settlement with a California boy on May 27, just hours before opening arguments were to start in what would have been the third opportunity for a Philadelphia jury to weigh the connection between antipsychotic drug Risperdal and abnormal breast growth in youth. The settlement was in the case of plaintiff Christopher Walker, which is part of Philadelphia’s mass tort program involving the drug. The terms of the settlement are confidential.

The plaintiffs in this case are represented by Steven Sheller and Christopher Gomez of Sheller and Thomas Kline of Kline & Specter. They did a very good job in this very important case. The case is Christopher Walker v. Janssen Pharmaceuticals Inc., in the Court of Common Pleas of Philadelphia County, Pennsylvania.